Twist Bioscience (NASDAQ:TWST) CEO Emily Leproust Sells 18,880 Shares of Stock

Posted by Brian Himes on Jun 26th, 2026

Twist Bioscience Corporation (NASDAQ:TWST – Get Free Report) CEO Emily Leproust sold 18,880 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $95.00, for a total transaction of $1,793,600.00. Following the sale, the chief executive officer directly owned 824,039 shares of the company’s stock, valued at approximately $78,283,705. This represents a 2.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST traded up $3.19 during midday trading on Friday, hitting $99.84. The company had a trading volume of 4,274,502 shares, compared to its average volume of 1,512,186. The company has a market cap of $6.22 billion, a price-to-earnings ratio of -75.07 and a beta of 2.23. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.70 and a quick ratio of 2.42. The company has a fifty day moving average of $66.16 and a two-hundred day moving average of $51.10. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $104.23.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last posted its quarterly earnings data on Monday, May 4th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.22). The company had revenue of $110.72 million during the quarter, compared to the consensus estimate of $107.64 million. Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The firm’s quarterly revenue was up 19.3% compared to the same quarter last year. During the same period last year, the business earned ($0.66) EPS. On average, equities research analysts expect that Twist Bioscience Corporation will post -2.02 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Barclays upped their price objective on Twist Bioscience from $65.00 to $95.00 and gave the stock an “overweight” rating in a research note on Wednesday. UBS Group set a $89.00 price target on Twist Bioscience in a research note on Monday, June 15th. Robert W. Baird raised their target price on shares of Twist Bioscience from $50.00 to $65.00 and gave the company an “outperform” rating in a research note on Tuesday, May 5th. Canaccord Genuity Group assumed coverage on shares of Twist Bioscience in a report on Monday, June 15th. They issued a “buy” rating and a $90.00 price target on the stock. Finally, Piper Sandler started coverage on shares of Twist Bioscience in a report on Thursday, June 11th. They set an “overweight” rating and a $85.00 price objective for the company. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $74.60.

View Our Latest Stock Analysis on Twist Bioscience

Hedge Funds Weigh In On Twist Bioscience

A number of institutional investors and hedge funds have recently made changes to their positions in the business. EdgePoint Investment Group Inc. increased its stake in Twist Bioscience by 71.1% in the third quarter. EdgePoint Investment Group Inc. now owns 4,082,319 shares of the company’s stock worth $114,876,000 after purchasing an additional 1,696,377 shares during the period. First Light Asset Management LLC lifted its holdings in Twist Bioscience by 26.4% during the 3rd quarter. First Light Asset Management LLC now owns 1,194,883 shares of the company’s stock valued at $33,624,000 after buying an additional 249,850 shares in the last quarter. SG Americas Securities LLC boosted its position in Twist Bioscience by 350.3% in the 4th quarter. SG Americas Securities LLC now owns 76,484 shares of the company’s stock valued at $2,426,000 after buying an additional 59,500 shares during the period. William Blair Investment Management LLC grew its stake in Twist Bioscience by 6.0% in the 3rd quarter. William Blair Investment Management LLC now owns 4,142,283 shares of the company’s stock worth $116,564,000 after acquiring an additional 235,679 shares in the last quarter. Finally, Rafferty Asset Management LLC grew its stake in Twist Bioscience by 51.0% in the 3rd quarter. Rafferty Asset Management LLC now owns 114,268 shares of the company’s stock worth $3,216,000 after acquiring an additional 38,608 shares in the last quarter.

About Twist Bioscience

(Get Free Report)

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.